Welcome to our dedicated page for Ovation news (Ticker: OVATF), a resource for investors and traders seeking the latest updates and insights on Ovation stock.
Ovation Science Inc. (OVATF) regularly issues news updates that highlight its progress in topical and transdermal cannabinoid products, Invisicare skin delivery technology and licensing partnerships. Company news often covers new licensing agreements in U.S. states and Canada, product launches with multi-state cannabis operators, and developments in its intellectual property portfolio, including patents for cannabinoid transdermal delivery.
Investors and industry observers following OVATF news can read about exclusive agreements with partners such as Planet 13 in Nevada and Florida, PA Options for Wellness in Pennsylvania, MidWest Roots in Missouri and Ripco Processing in Canada. Releases describe how these partners manufacture, market and distribute Ovation’s formulations in regulated markets, and how Ovation earns royalties based on sales. Updates also discuss the performance of Ovation’s topicals in laboratory testing and their positioning within medical, wellness and beauty categories.
Ovation’s news flow also features strategic collaborations, including its enhanced partnership with Skinvisible Pharmaceuticals to apply Invisicare technology and cannabinoid formulations in areas such as obesity and metabolic health. Regulatory context, such as U.S. cannabis rescheduling, is frequently discussed in terms of potential opportunities for science-based topical products and licensing expansion.
This OVATF news page aggregates press releases and announcements so readers can track licensing milestones, product rollouts, patent activity and strategic initiatives related to Ovation’s Invisicare-powered cannabinoid topicals. For those monitoring the company’s evolution within the cannabis and wellness ecosystem, it provides a centralized view of key corporate developments over time.
Ovation Science Inc. has announced a new Supply and Distribution Agreement with Golfer's CBD Ltd. for its CBD topical products in the USA, UK, and Europe. This partnership aims to penetrate the lucrative golf market, which includes approximately 66.6 million golfers worldwide. By leveraging Golfer's CBD's established e-commerce and retail distribution channels, Ovation expects to generate immediate monthly revenues. Their patented skin delivery technology, Invisicare, allows for superior absorption of cannabinoids, giving Ovation a competitive edge. The initial launch in the USA is scheduled for April 2023.
Ovation Science Inc. (CSE: OVAT, OTCQB: OVATF) will exhibit at the MJ Unpacked conference from September 28-30, 2022, in Las Vegas. The company aims to meet potential licensees to promote its award-winning transdermal formulations and highlight licensing opportunities for its patented skin delivery technology, Invisicare®. With new patent protection until 2041 and expansion in states like Oklahoma and Missouri, Ovation anticipates significant interest in its products. CEO Terry Howlett emphasized the company's focus on effective cannabinoid delivery and the unique advantages of their formulations.
Ovation Science Inc. has been awarded a patent for its transdermal creams formulated with CBD and THC, valid until February 2041. This patent strengthens the company's market position by protecting its proprietary drug delivery system, Invisicare. It covers the composition and method for delivering CBD and THC through the skin. Ovation has also expanded its licensing to four additional U.S. states, increasing its market reach to over 2,800 dispensaries. The company’s innovative approach has resulted in products showing significantly better absorption rates compared to competitors.
Ovation Science Inc. has announced an exclusive licensing agreement with Stash House Distribution to expand its cannabis formulations into Oklahoma, Missouri, New Mexico, and Mississippi. This agreement aims to increase the company's market presence from 92 dispensaries in Nevada to over 2,800 dispensaries across five states. Ovation's products utilize the patented Invisicare® technology for enhanced cannabinoid delivery, promising a significant increase in revenue through royalties based on wholesale sales. The launch is expected to occur in Q4 of 2022.
Ovation Science Inc. has launched new high-dose CBD formulations in response to the growing CBD market. The company developed a transdermal cream with 1500mg of CBD per ounce and a beauty line offering 200mg per ounce for anti-aging creams and 2000mg for body lotion. The demand for high-dose CBD topicals is increasing, supported by a projected CAGR of 21.2% for CBD products from 2021 to 2028. Ovation aims to expand its market presence beyond Nevada, where its products rank among the top five in sales at dispensaries.
Ovation Science Inc. reported a 15% increase in royalty revenue due to strong sales of its topical cannabis products in Nevada. As of November 30, five of the top ten topical products sold in the state are from Ovation. The company is leveraging its patented Invisicare technology, which enhances the absorption of CBD and THC. Overall cannabis sales in the U.S. for 2021 are projected to reach nearly $31 billion, an increase of 41% over 2020. Ovation aims to expand its licensing model to other states and engage in consumer packaged goods (CPG) opportunities in the upcoming year.
Ovation Science Inc. (CSE:OVAT, OTCQB:OVATF) has announced a new partnership with Pivot Protection Resource, a national distributor for its DermSafe non-alcohol hand sanitizer lotion. This move aims to enhance workplace safety amid the ongoing pandemic, particularly with the rising prevalence of the Delta variant. DermSafe, which uses 4% chlorhexidine gluconate, offers superior germ protection without the drying effects of alcohol. It has shown a 99.97% reduction in the human coronavirus in tests and is recognized by the Canadian Dermatology Review Panel.
Ovation Science Inc. (CSE:OVAT, OTC:OVATF) reports a surge in sales of its non-alcohol hand sanitizer, DermSafe, to athletes across Canada. DermSafe, which contains 4% chlorhexidine gluconate, offers long-lasting germ protection without drying hands. It has shown a 99.97% reduction in the human coronavirus strain OC43. The product has received a Seal of Approval from the Canadian Dermatology Review Panel. Management emphasizes the necessity of such products as athletes return to sports.
Ovation Science Inc. (CSE:OVAT)(OTCQB:OVATF) has launched an online campaign to promote its DermSafe® hand sanitizer, which utilizes Invisicare® technology instead of alcohol. This initiative will feature over 100 articles on Canadian Skin Information's websites, attracting more than 25,000 monthly visitors. DermSafe, effective against COVID-19 with a 99.97% reduction in virus, addresses skin conditions such as dryness and eczema. The campaign aims to boost sales amid retail lockdowns in Canada, providing easy access for consumers.
Ovation Science Inc. has provided an update on its ongoing development of topical and transdermal cannabis products utilizing its patented Invisicare® technology. The company has developed over 30 products, including health and wellness and beauty items, with various CBD to THC ratios. They successfully established a strong market presence in Nevada and aim to expand into other U.S. states. The topical cannabis market is projected to reach $4.5 billion by 2025, marking a significant growth opportunity for Ovation and its unique formulation capabilities.